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Introduction
Cluster headache (CH) is a severe form of primary
headache, characterized by trigeminal-autonomic system
activation. Bouts, lasting 15-180 minutes, occur 1-8
times a day, for a period persisting for weeks or months,
followed by a full remission. However, about 10-15% of
patients have no remission periods and their CH is
defined chronic (CCH). While symptomatic treatment is
often effective, preventive treatments are limited. Our
group has already reported the case of a patient affected
by refractory CCH who underwent a complete and sus-
tained response to rotigotine, a non-ergoline D3-like
receptor agonist, also with a 5HT1A effect, admini-
strated by transdermal patches. Here we report a case
series of patients that have tried transdermal rotigotine
for their drug-resistant CH.
Methods
We recruited 14 CH drug-resistant patients (11 chronic)
that accepted to try transdermal rotigotine to treat their
CH, increasing dose weekly of 2 mg up to 6 mg, accord-
ing to our previous report.
Results
Out of 3 episodic CH (ECH) patients, two had an
improvement of bouts at 4 mg, but obtained a stable bene-
fit at 6 mg; after the presumed end of their CH period they
progressively discontinued the patches and the CH did not
come back till the next cluster period. The other ECH
patient did not respond at 6 mg, than the dose was further
increased to 8 mg, without benefit thus the treatment was
interrupted. Out of 11 CCH patients, 8 were considered
responders since CH disappeared (5 cases) or significantly
decreased (more than 50% of reduction in terms of bouts
frequency and intensity, or symptomatic consumption).
Six patients had an early benefit at 4 mg but stable
response at 6 mg. In two cases the dose was further
increased to 8 mg since CH worsened. Two patients sud-
denly discontinued treatment by an ‘overnight-switch’ to
pramipexole due to late dermatological reactions; one of
them remained CH free after the switch. Patients who did
not respond at 6 mg continued to not respond at 8 mg
and treatment was interrupted.
Discussion
This case series seems to confirm our early observation
that transdermal rotigotine could act as preventive treat-
ment in cluster headache. Further, this series give us
other information: 1) Rotigotine could be increased up to
8 mg if necessary; 2) If up to 6 mg it does not act, it will
not act at 8; 3) Some late dermatological complications
could occur during the treatment.
Written informed consent to publication was obtained
from the patient(s).
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